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Abstract. The development of statistical approaches for the joint mod-
elling of the temporal changes of imaging, biochemical, and clinical bio-
markers is of paramount importance for improving the understanding of
neurodegenerative disorders, and for providing a reference for the predic-
tion and quantification of the pathology in unseen individuals. Nonethe-
less, the use of disease progression models for probabilistic predictions
still requires investigation, for example for accounting for missing obser-
vations in clinical data, and for accurate uncertainty quantification. We
tackle this problem by proposing a novel Gaussian process-based method
for the joint modeling of imaging and clinical biomarker progressions
from time series of individual observations. The model is formulated to
account for individual random effects and time reparameterization, al-
lowing non-parametric estimates of the biomarker evolution, as well as
high flexibility in specifying correlation structure, and time transforma-
tion models. Thanks to the Bayesian formulation, the model naturally
accounts for missing data, and allows for uncertainty quantification in the
estimate of evolutions, as well as for probabilistic prediction of disease
staging in unseen patients. The experimental results show that the pro-
posed model provides a biologically plausible description of the evolution
of Alzheimer’s pathology across the whole disease time-span as well as
remarkable predictive performance when tested on a large clinical cohort
with missing observations.
1 Introduction
Neurodegenerative disorders (NDDs), such as Alzheimer’s disease (AD), are
characterised by the progressive pathological alteration of the brain’s biochemi-
cal processes and morphology, and ultimately lead to the irreversible impairment
? Data used in preparation of this article were obtained from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) database (www.loni.usc.edu/ADNI). As such,
the investigators within the ADNI contributed to the design and implementa-
tion of ADNI and/or provided data but did not participate in analysis or writ-
ing of this report. A complete listing of ADNI investigators can be found at:
www.loni.usc.edu/ADNI/Collaboration/ADNI_Authorship_list.pdf
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2of cognitive functions. The correct understanding of the relationship between
the different pathological features is of paramount importance for improving
the identification of pathological changes in patients, and for better treatment.
To this end, the recent availability of collections of imaging and clinical data in
NDDs is a unique opportunity to define statistical models for the joint modelling
of the temporal changes of imaging, biochemical, and clinical biomarkers.
The goal of disease progression modeling in NDDs is twofolds: 1) quantifying
the dynamics of NDDs along with the related temporal relationship between
different biomarkers, and 2) staging patients based on individual observations for
diagnostic and interventional purposes. The related challenge is in the definition
of optimal methods to integrate and jointly analyze the heterogeneous and highly
multi-modal information available to clinicians. Moreover, longitudinal clinical
datasets of NDDs generally lack of a well-defined temporal reference, since the
onset of the pathology may vary across individuals according to genetic and
environmental factors [12]. Therefore, age or visit date information are biased
time references for the individual longitudinal measurements.
To tackle this problem, in [3] the authors proposed to model the temporal
biomarker trajectories as a random effect regression problem, building on the
well established theory of self-modeling regression [6]. Practically, the trajecto-
ries are modelled by monotonic B-splines, and the estimation is performed by
subsequent minimization of the partial residuals sum of squares associated with
regression parameters and individual time shift, respectively. Based on the as-
sumption of a logistic curve shape for the average biomarker trajectories, [11]
frames the random effect regression model in a Riemannian setting, in which the
random effects identify individual time-shift and acceleration factors. Finally,
image-based progression models have been recently proposed [13,2], based on
time-reparameterization of voxel/mesh-based measures. While the main focus
of current works mainly concerns the modeling of neurodegeneration, the use
of disease progression models for predictive purposes is much less investigated.
Predictive models of patient staging were proposed within the setting of event
based models [4], or still through random effect modeling [5]. However, the event
based model relies on the coarse binary discretization of the biomarker changes,
and does not account for longitudinal observations, while the model proposed
in [5] requires cohorts with known disease onset, and therefore does not easily
generalise to the study of general clinical populations.
In this study we propose an unified approach to the consistent disease pro-
gression modeling and probabilistic prediction of clinical data, by introducing
a Bayesian regression framework of imaging and clinical biomarker progressions
from time series of individual observations. The model is based on Gaussian pro-
cess (GP) regression, and is formulated to account for individual random effects
and time reparameterization, as well to naturally account for missing observa-
tions. The methodological contribution of this study consists in reformulating
disease progression modeling within a Bayesian context, allowing non-parametric
estimates of the biomarker evolution, as well as high flexibility in specifying ran-
dom effects structure, and time reparameterization models. The uniqueness of
3the time transformation is enforced by imposing a monotonicity constraint on
the trajectories, via a prior on the temporal derivatives, while the model is
computationally efficient thanks to the block-wise algebraic structure of the GP
covariance function. From the application point of view, the proposed approach
enables novel applications of disease progression modeling such as the proba-
bilistic prediction of disease staging in unseen patients. Moreover, the model
naturally accounts for missing data, and allows for uncertainty quantification of
both evolutions and parameters.
Section 2 introduces the proposed GP regression model of joint temporal pro-
gression of biomarkers, along with the prior derivatives specification. The result-
ing posterior and approximated inference scheme through expectation propaga-
tion (EP) is described in Section 3. Finally, Section 4 illustrates the validation of
our model on i) synthetic data and ii) clinical and multivariate imaging measure-
ments from a cohort of 517 amyloid positive individuals of the ADNI database.
The experimental results show that our model provides a biologically plausible
description of the evolution of AD across the whole disease time-span, as well
as statistically significant prediction of disease staging and high classification
accuracy on unseen and incomplete testing data.
2 Gaussian process-based random effect modeling of
longitudinal progressions
In what follows, longitudinal measurements of Nb biomarkers {b1, . . . , bNb} over
time are given for N individuals.
We represent the longitudinal biomarker’s measures associated with each
individual j as a multidimensional array (yj(t1),yj(t2), . . . ,yj(tkj ))> sampled
at kj multiple time points t = {t1, t2, . . . , tkj}. Although different biomarkers
may be in reality sampled at different time-points, for sake of notation simplicity
in what follows we will assume, without loss of generality, that the sampling time
is common among them. The observations for individual j at a single time point
t are thus a random sample from the following generative model:
yj(t) =
(
yjb1(t), y
j
b2
(t), . . . , yjbNb
(t)
)>
= f(t) + νj(t) + , (1)
where f(t) = (fb1(t), fb2(t) . . . , fbNb (t))
> is the fixed effect function modelling
the biomarker’s longitudinal evolution, νj(t) = (νjb1(t), ν
j
b2
(t), . . . , νjbNb
(t))> is
the individual random effect, and  = (b1 , b2 , . . . , bNb )
> is observational noise
independent from time. The group-wise evolution is modelled as a zero-mean
GP, f ∼ GP(0, ΣG), the individual random effects are assumed to be Gaussian
distributed correlated signal νj ∼ N (0, ΣS), while the observational noise is
assumed to be a Gaussian heteroskedastic term  ∼ N (0, Σ), where Σ is a
diagonal matrix diag[σ2b1,σ
2
b2, . . . ,σ
2
bNb
].
Fixed Effect Process. The covariance function ΣG describes the biomarkers
temporal variability, and is represented as a block-diagonal matrix
ΣG(f , f) = diag[Σb1(fb1 , fb1), Σb2(fb2 , fb2), . . . , ΣbNb (fbNb , fbNb )], (2)
4where each block represents the within-biomarker temporal covariance expressed
as a negative squared exponential function:
Σb(fb(t1), fb(t2)) = ηb exp
(
− (t1 − t2)
2
2 l2b
)
, (3)
and where the parameters ηb and lb are the marginal variance and length-scale
of the biomarker’s temporal evolution, respectively.
Individual Random Effects. The random covariance function ΣS models the
individual deviation from the fixed effect, and is represented as a block-diagonal
matrix
ΣS(ν
j ,νj) = diag[Σjb1(ν
j
b1
,νjb1), Σ
j
b2
(νjb2 ,ν
j
b2
), . . . , ΣbjNb
(νjbNb
,νjbNb
)],
where each block Σjb corresponds to the covariance function associated with
the individual process νjb(t). Thanks to the flexibility of the proposed generative
model, any form of the random effect covariance ΣS can be easily specified in or-
der to model the subject-specific biomarkers’ progression. In what follows we will
use a linear covariance form Σjb (ν
j
b(t1),ν
j
b(t2)) = (σ
j
b)
2
(
(t1 − t)(t2 − t)
)
, where
t is the average observational time for individual j, if more than 4 measurements
were available, and i.i.d. Gaussian covariance form Σjb (ν
j
b(t1),ν
j
b(t2)) = (σ
j
b)
2 if
2 or 3 measurements were available, while assigning it to 0 otherwise. This choice
is motivated by stability concerns, in order to keep the model complexity com-
patible with the generally limited number of measurements available for each
individual.
Individual time transformation. The generative model (1) is based on the
key assumption that the longitudinal observations across different individuals are
defined with respect to the same temporal reference. This assumption may be
invalid when the temporal alignment of the individual observations with respect
to the common group-wise model is unknown, for instance in the typical scenario
of a clinical trial in AD where the patients’ observational time is relative to the
common baseline, and where the disease onset is a latent event (past or future)
which is not directly measurable. We assume that each individual measurement is
made with respect to an absolute time-frame τ through a time-warping function
t = φj(τ) that models the time-reparameterization with respect to the common
group-wise evolution. Model (1) can thus be reparameterized as
yj(φj(τ)) = f(φj(τ)) + νj(φj(τ)) + . (4)
The present formulation allows the specification of any kind of time transfor-
mation, and in what follows we shall focus on the modelling of a linear reparam-
eterization of the observational time φj(τ) = τ + dj . This modeling assumption
is mostly motivated by the choice of working with a reasonably limited num-
ber of parameters, compatibly with the generally short follow-up time available
per individual (cfr. Table 3). Within this setting, the time-shift dj encodes the
disease stage associated with the individual relatively to the group-wise model.
5Overall, model (4) is identified by (Nj + 3)Nb +Nj parameters, represented
by the fixed effects and noise θG = {ηbk , lbk , bk}Nbk=1, by the individual random
effects parameters θjG = {σjbk}Nbk=1 and by the time-shifts dj .
Monotonic constraint in multimodal GP regression. Due to the non-
parametric nature of Gaussian process regression, we need an additional con-
straint on model (4) in order to identify a unique solution for the time-warp. By
assuming a steady temporal evolution of biomarkers from normal to pathological
values, we shall assume that the biomarker trajectories described by (4) follow a
(quasi) monotonic behaviour. This requirement can be implemented by imposing
a prior positivity constraint on the derivatives of the GP function f . Inspired by
[10], we impose a monotonicity constraint by assuming a probit-likelihood for the
derivative measurements m(t) associated with the derivative process f˙(t) = df(t)dt
at time t:
p(m(t)|f˙(t)) = Φ
(
1
λ
f˙(t)
)
, (5)
with Φ(z) =
∫ z
−∞N (x|0, 1) dx. The quantity λ > 0 is an additional model pa-
rameter controlling the degree of positivity enforced on the derivative process,
with values approaching to zero for stronger monotonicity constraint. In what
follows, the monotonicity of each biomarker is controlled by placing 10 derivative
points equally spaced on the observation domain, and by fixing the Nb deriva-
tive parameters {λbk}Nbk=1 to the value of e-6. This choice for the parameter is
motivated by the need to enforce a strong monotonicity constraint, necessary for
the stability of the initial time-shift estimation.
On adding a monotonic constraint to the individual observations. By
following a similar construction, we could equally enforce a monotonic behaviour
to the random effects associated with the individual trajectories. This additional
constraint would however come with a cumbersome increase of the model com-
plexity, since it would introduce an additional layer of virtual derivative parame-
ters (with associated location) per individual. Moreover, while we are interested
in modeling a globally monotonic biomarker trajectory on the fixed parame-
ters, we relax this constraint at the individual level, since some subjects may
be characterised by non strictly monotonic time-series due to specific clinical
conditions.
3 Joint Model: marginal likelihood and inference
Given the sets of individual biomarker measurements y = {(yj(ti))kji=1}Nj=1, and
of D control derivatives m = {mbk(t′l)}Dl=1 at points t′ = {t′l}Dl=1 for the progres-
sion of each biomarker bk, the random effect GP model posterior is:
p
(
f , f˙ ,νj |y,m
)
=
1
Z
p(f , f˙ |t, t′)p(ν|t)p(y|f ,ν)p(m|f˙)
= p(f , f˙ |t, t′)p(ν|t)p(y|f ,ν)
∏
k
∏
l
Φ
(
1
λ
f˙bk(t
′
l)
)
, (6)
6where ν = {νj}Nj=1. Thanks to the linearity of GPs under derivation, we have
that Cov
(
f(t), f˙(t′)
)
= dCov(f(t),f(t
′))
dt′ , and that the joint distribution p
(
f , f˙ |t, t′
)
is again a GP:
p
(
f , f˙ ,νj |t, t′
)
∼ GP (fjoint|0, Σjoint)
fjoint =
(
f
f˙
)
∼ N
[(
0
0
)
,
(
ΣG(f(t), f(t))
∂ΣG(f(t),f(t
′))
∂t′
dΣG(f(t
′),f(t))
dt′
d2ΣG(f(t
′),f(t′))
dt′2
)]
.
3.1 Approximated inference with Expectation Propagation
Due to the non-Gaussianity of the derivative likelihood term, the direct inference
on the posterior (6) is not possible due to its analytically intractable form. For
this reason, we employ an approximate inference scheme based on expectation
propagation (EP) [9,8]. Following [10], we compute an approximated posterior
distribution q
(
f , f˙ ,νj |yj ,m
)
by replacing the derivative likelihood terms with
local un-normalized Gaussian approximations:
q
(
f , f˙ ,νj |yj ,m
)
=
1
ZEP
p(f , f˙ |t, t′)p(ν|t)p(y|f ,ν)
∏
k
∏
l
Z˜klN (f˙bk(t′l)|µ˜kl, σ˜2kl),
(7)
where
∏
k
∏
l Z˜klN (f˙bk(t′l)|µ˜kl, σ˜2kl) = N (µ˜, Σ˜)
∏
k,l Z˜kl, with µ˜ = [µ˜kl], and Σ˜
is a diagonal matrix with elements σ˜2kl. It follows that the marginal posterior
has a Gaussian form, q
(
f , f˙ ,νj |yj ,m
)
∼ N (µ, Σ), with µ = ΣΣ˜−1µ˜joint , and
Σ = (Σ−1joint + Σ˜
−1
joint)
−1, where
µ˜joint =
(
y
µ˜
)
, and Σ˜joint =
(
Σ +ΣS 0
0 Σ˜
)
. (8)
Estimating the EP parameters. The EP update of the local Gaussian ap-
proximation parameters is classically done by iterative moment matching with
respect to the product between the cavity distributions q−k′l′
(
f˙bk′ (t
′
l′)
)
and the
target likelihood term Φ
(
1
λ f˙bk′ (t
′
l′)
)
. In the GP case the cavity distribution has
a straightforward Gaussian form:
q−k′l′
(
f˙bk′ (t
′
l′)
)
=
∫ ∏
k 6=k′
∏
l 6=l′
Z˜klN (f˙bk(t′l)|µ˜kl, σ˜2kl)df˙bk(t′l)
∼ N (f˙bk′ (t′l′)|µ−k′l′ , σ−k′l′). (9)
As shown in [10] for univariate monotonic regression, moments and updates of
the approximation parameters can be computed in an analogous manner as in
the classical GP classification problem [9].
73.2 Marginal Likelihood and hyper-parameter estimation
The model’s log-marginal likelihood under the EP approximation is:
logL = −1
2
log |Σjoint + Σ˜joint| − 1
2
µ˜Tjoint(Σjoint + Σ˜joint)
−1µ˜joint +∑
k
∑
l
(µ−kl − µ˜kl)2
2(σ2−kl) + σ˜
2
kl)
+
∑
k
∑
l
logΦ(
µ−kl√
λ2k + σ
2
−kl)
) +
1
2
∑
k
∑
l
log(σ2−kl + σ˜
2
kl). (10)
In what follows, the optimal parameters are obtained by maximising logL through
conjugate gradient descent, via alternate optimization between the hyper-parameters
θG and θ
j
G, and the individuals’ time-shifts d
j . The position of the derivative
points was updated at each iteration, according to the changes of the GP do-
main. Regularisation was also enforced by introducing Gaussian priors for the
parameters θG and θ
j
G. We note that the block structure of the GP covariance
allows the computation of the gradients with respect to the biomarkers’ and
individual parameters by working on matrices of much smaller dimension than
the one of the whole GP, thus considerably improving the numerical stability
and the computational efficiency of the optimization procedure.
3.3 Prediction of observations and individual staging
Gaussian processes naturally allow probabilistic predictions given the observed
data. At any given time point t∗, the posterior biomarker distribution has the
Gaussian form p(f∗|t∗,y, t,m, t′) ∼ N (f∗|µ∗, Σ∗) with parameters:
µ∗ = ΣG(f(t∗), f(t))(Σjoint + Σ˜joint)−1µ˜joint (11)
Σ∗ = ΣG(f(t∗), f(t∗))−ΣG(f(t∗), f(t))(Σjoint + Σ˜joint)−1ΣG(f(t), f(t∗)).(12)
We also derive a probabilistic model for the individual temporal staging given a
set of biomarker observations y∗, thanks to the Bayes formula:
p(t∗|y∗,y, t,m, t′) = p(y∗|t∗,y, t,m, t′)p(t∗)/p(y∗|y, t,m, t′), (13)
which we compute by assuming an uniform distribution on t∗, and by noting that
p(y∗|t∗,y, t,m, t′) ∼ N (µ∗, Σ∗ + Σ). In particular, the joint covariance form
ΣG(f(t
∗), f(t∗)) can be specified in order to account for incomplete data, and
thus generalizes the GP model for predictions in presence of missing biomarker
observations.
84 Experiments
4.1 Synthetic multivariate progressions
We benchmarked the model with respect to synthetic multivariate biomarker
progressions. We generated random multivariate sigmoid functions for Nb bio-
markers, f(τ) = (fb1(τ), fb2(τ), . . . , fbNb (τ))
>, with fbk(τ) = 1/(1+exp(−αkτ)),
τ ∈ [0, 15] and αk ∼ N (0, .06), and we sampled N individual noisy trajectories
at time points τ jk : y
j
k(τ
j
k) = fk(τ
j
k)+,  ∼ N (0, σ2). For each individual we used
the same initial sampling time point for every biomarker, while the number of
samples per biomarker was allowed to independently vary between 1 and 4. The
individual time points were subsequently centered by their mean µjk to obtain
shifted time-points tjk = τ
j
k − µjk defined in the interval [−2, 2].
The model was applied to estimate biomarker progressions and individual
time-shifts with respect to different combinations of trajectory noise σ, sample
size N , and number of biomarkers Nb. The accuracy of the model in recon-
structing the original time series was quantified by Pearson’s correlation be-
tween the estimated time-shift dj and the original individual time reference.
The experiments were repeated 10 times for each configuration of parameters
σ ∈ {0.1, 0.2, 0.3, 0.4}, Nb ∈ {4, 8}, and N ∈ {20, 100}.
Results. Table 1 reports summary correlations between time-shift estimation
and the ground truth individual sampling time. The correlation values are gen-
erally high, and increase with lower noise levels. Interestingly, the increase in
number of modelled biomarkers is associated with a better performance in re-
covering the underlying disease staging. We also observe that larger sample sizes
are associated with higher correlation values, especially with increasing noise
levels. We note however an exception for the case σ = 0.1 where, although the
overall performance is still high, the correlation slightly decreases with N = 100.
4.2 Longitudinal modelling of Alzheimer’s disease progression
We collected longitudinal measurements for the ADNI individuals with baseline
values of CSF Aβ amyloid lower than the nominal values of 192 pg/ml. This
preliminary selection is aimed to validate the model on a clinical population
likely to represent the whole disease time-span.
The model was trained on a group including normal individuals, mild cogni-
tive impairment subjects converted to AD (MCI conv), and AD patients having
N = 20 N = 100
σ σ
0.1 0.2 0.3 0.4 0.1 0.2 0.3 .4
Nb
4 .95 (.03) .86 (.08) .71 (.17) .46 (.29) .91 (.04) .89(.04) .76 (.17) .75 (.12)
8 .97 (.01) .91 (.06) .86 (.06) .66 (.3) .94 (.04) .94 (.02) .88 (.06) .84 (.07)
Table 1: Mean (sd) R2 correlation coefficient across folds between estimated
individual time-shifts and ground truth time reference.
9Group N Age Sex (% females) ADAS13 Hippo volume (mm3) AV45
Training data
NL 76 75.8 (6) 53 9.5 (4.4) 7358 (762) 1.24 (0.2)
MCI conv 57 72.7 (7) 42 20.3 (6.8) 6464 (861) 1.44 (0.2)
AD 21 72.7 (10) 43 29.3 (8.7) 5872 (988) 1.4 (0.2)
Testing data
NL 30 77.5 (6) 43 11.1 (4.1) 7137 (800) 1.03 (0.14)
MCI stable 164 73.4 (6.9) 39 15.5 (6.19) 7028 (1009) 1.28 (0.2)
MCI conv 71 75.4 (6.7) 40 21.3 (5.4) 5882 (8644) NA
AD 98 74.7 (8) 40 28.6 (8) 5709 (1105) 1.59 (0.1)
Table 2: Baseline clinical and sociodemographic information for the study cohort.
NA: no observations available for the considered group. NL: normal individuals,
MCI: mild cognitive impairment, AD: Alzheimer’s patients.
at least one measurement for each of the following biomarkers: volumetric mea-
sures (hippocampal, ventricular, entorhinal, and whole brain volumes), glucose
metabolism (average normalized FDG uptake in prefrontal cortex, anterior cin-
gulate, precuneus and parietal cortex), brain amyloidosys (average normalized
AV45 uptake in frontal cortex, anterior cingulate, precuneus and parietal cortex),
and cognitive function measured by common cognitive questionnaires (ADAS13,
RAVLT learning score, FAQ). The testing set was composed by the remaining
subjects with at least a missing biomarker, as well as by the subgroup of MCI
non converted to AD during the observational time (MCI stable). The volumet-
ric measures were scaled by the individual total intracranial volume, and all the
biomarkers measurements were converted into quantile scores (0 to 1 for normal
to abnormal values). Table 2 shows baseline clinical and sociodemographic in-
formation of the individuals used respectively in training and testing set, while
in Table 3 we report the average follow-up time and the ratio of missing data of
the pooled sample.
The model was applied in order to estimate the temporal biomarker evolu-
tion and the disease stage associated with each individual in training and testing
set. The plausibility of the model was assessed by i) group-wise comparison of
the predicted time-shift, ii) prediction of conversion to AD in the MCI testing
group, and iii) correlation with respect to the time to AD diagnosis for the MCI
individuals subsequently converted to AD. We finally compared the progression
Ventr Hippo Ent Whole Brain ADAS13 FAQ RAVLT AV45 FDG
Training data
2.4 (0) 2.4 (0) 2.4 (0) 2.4 (0) 3.2 (0) 3.2 (0) 3.2 (0) 1.3 (0) 1.9 (0)
Testing data
1.8 (.1) 1.8 (.1) 1.8 (.1) 1.8 (.1) 2.4 (0) 2.5 (0) 2.4 (0) 1.3 (65) 1.6 (31)
Table 3: Average follow-up years and percentage of individuals with missing data
for each biomarker (in parenthesis).
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Fig. 1: Modelled biomarker progression in Aβ amyloid positive individuals
(solid/dashed lines: mean ± sd). NL: normal individuals, MCI: mild cognitive
impairment converted to AD, AD: Alzheimer’s patients.
modelled with our approach with respect to the one estimated with the method
proposed in [3]. The method was applied to the training data by using the stan-
dard parameters defined in the R package grace4.
Results. The estimated biomarker progression (Figure 1) shows a biologically
plausible description of the pathological evolution, compatible with previous
findings in longitudinal studies in familial AD [1]. The progression is defined
on a time scale spanning roughly 20 years, and is characterized at the initial
stages by high-levels of AV45, followed by an increase in ventricles volume and
abnormality of FDG uptake. These latter measures are however heterogeneously
distributed across clinical groups, and with rather large variability. The evolution
is further characterized by increasing abnormality of the volumetric measures,
and finally by the steady worsening of neuropsychological scores such as FAQ.
Figure 2 shows the posterior predicted distribution of the individual time shift.
Healthy individuals are associated with the early stages of the pathology in both
training and testing data, while MCI and AD patients are characterized by re-
spectively intermediate and late predicted progression stages. The group-wise
comparison between the expected time-shifts is statistically significant between
each group pairs (p <1e-4). Furthermore, the temporal positioning of the non
converting MCI lies between controls and MCI converters: when using the tem-
poral cut-off based on the 10th quantile of the time-shift distribution in the
training AD population (t = 3.6 years) we obtained an accuracy of 0.84 for the
discrimination between MCI converters and stable in the testing data. We also
4 https://mdonohue.bitbucket.io/grace/
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Fig. 2: Posterior prediction for the individual time shift in training (top) and
testing (bottom) data. Healthy individuals are generally displaced at the early
stages of the pathology, while the predictions for MCI and AD patients are
associated with respectively intermediate and late progression stages. NL: normal
individuals, MCI: mild cognitive impairment, AD: Alzheimer’s patients.
measured a negative correlation with respect to the time to AD diagnosis in
training, testing, and pooled MCI converter groups, with R2 respectively equal
to −0.20 (p = 0.1), −0.28 (p = 0.01), and −0.28 (p = 0.001). Finally, when ap-
plying [3] to the training data we measured a strong correlation between the
resulting individual time-shifts and those obtained with our method (R2 = 0.89,
p <1e-16). Nevertheless, our estimates provided consistently larger effect sizes
for the group-wise separation: (1.96,1.36,0.57) with our methods and (1.74, 1.18,
0.47) with grace for AD vs NL, MCI vs NL, and AD vs MCI, respectively.
5 Conclusions
We proposed a unified GP-based approach to disease progression modeling from
time-series of biomarker measurements enabling novel applications beyond the
state-of-art, such as the probabilistic prediction of disease staging in unseen pa-
tients. Furthermore, the model naturally accounts for missing data, and provides
uncertainty quantification of the biomarker evolutions. The model provided re-
markable modeling and predictive performance when tested on a large clinical
cohort, and thus represents a promising instrument for the analysis of clinical
trials data.
Similarly to [3], in this work we focused on the modeling of disease staging
represented by a time translation. However, the proposed framework can natu-
rally account for more complex time transformations, provided that a sufficient
12
number of time points is available for each individual. Future extensions of this
model will focus on the quantification of the effect of each biomarkers in the
predictive performance, for example by integrating feature selection based on
automatic relevance determination. Moreover the present work can be extended
to model differential progressions underlying sub-pathologies, by framing the
proposed random effect regression within the realm of Gaussian process mixture
models. Finally, thanks to the flexibility of our framework, further extension of
the model will enable to integrate within (2) a spatio-temporal covariance model
(such as the efficient Kronecker form of [7]), to provide a unified framework for
jointly modelling time series of images and scalar biomarkers data in a coherent
fully Bayesian setting.
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